These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 37372439)

  • 21. Association of combinations of lipid parameters with carotid intima-media thickness and coronary artery calcium in the MESA (Multi-Ethnic Study of Atherosclerosis).
    Paramsothy P; Knopp RH; Bertoni AG; Blumenthal RS; Wasserman BA; Tsai MY; Rue T; Wong ND; Heckbert SR
    J Am Coll Cardiol; 2010 Sep; 56(13):1034-41. PubMed ID: 20846602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two-year treatment with rosuvastatin reduces carotid intima-media thickness in HIV type 1-infected patients receiving highly active antiretroviral therapy with asymptomatic atherosclerosis and moderate cardiovascular risk.
    Calza L; Manfredi R; Colangeli V; Trapani FF; Salvadori C; Magistrelli E; Danese I; Verucchi G; Serra C; Viale P
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):547-56. PubMed ID: 23098891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bivariate Genome-Wide Association Scan Identifies 6 Novel Loci Associated With Lipid Levels and Coronary Artery Disease.
    Siewert KM; Voight BF
    Circ Genom Precis Med; 2018 Dec; 11(12):e002239. PubMed ID: 30525989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple associated variants increase the heritability explained for plasma lipids and coronary artery disease.
    Tada H; Won HH; Melander O; Yang J; Peloso GM; Kathiresan S
    Circ Cardiovasc Genet; 2014 Oct; 7(5):583-7. PubMed ID: 25170055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis.
    Shah S; Casas JP; Drenos F; Whittaker J; Deanfield J; Swerdlow DI; Holmes MV; Kivimaki M; Langenberg C; Wareham N; Gertow K; Sennblad B; Strawbridge RJ; Baldassarre D; Veglia F; Tremoli E; Gigante B; de Faire U; Kumari M; Talmud PJ; Hamsten A; Humphries SE; Hingorani AD
    Circ Cardiovasc Genet; 2013 Feb; 6(1):63-72. PubMed ID: 23275344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention of atherosclerosis in patients living with HIV.
    De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
    Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment Trends, Effectiveness, and Safety of Statins on Lipid Goal Attainment in Chinese Percutaneous Coronary Intervention Patients: a Multicenter, Retrospective Cohort Study.
    Chen Y; Li D; Jing J; Yan H; Liu J; Shen Z; James S; Varenhorst C
    Clin Ther; 2017 Sep; 39(9):1827-1839.e1. PubMed ID: 28807393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
    Davidson M; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Setze C; Carlson DM; Stolzenbach J
    Cardiovasc Drugs Ther; 2012 Aug; 26(4):349-58. PubMed ID: 22622962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does baseline carotid intima-media thickness modify the effect of rosuvastatin when compared with placebo on carotid intima-media thickness progression? The METEOR study.
    Crouse JR; Bots ML; Evans GW; Palmer MK; O'Leary DH; Grobbee DE; Raichlen JS;
    Eur J Cardiovasc Prev Rehabil; 2010 Apr; 17(2):223-9. PubMed ID: 20038840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The associations between TMAO-related metabolites and blood lipids and the potential impact of rosuvastatin therapy.
    Xiong X; Zhou J; Fu Q; Xu X; Wei S; Yang S; Chen B
    Lipids Health Dis; 2022 Jul; 21(1):60. PubMed ID: 35864500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of recombinant human growth hormone therapy on blood lipid and carotid intima-media thickness in children with growth hormone deficiency.
    Chen M; Gan D; Luo Y; Rampersad S; Xu L; Yang S; Li N; Li H
    Pediatr Res; 2018 May; 83(5):954-960. PubMed ID: 29206809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin.
    Rader DJ; Davidson MH; Caplan RJ; Pears JS
    Am J Cardiol; 2003 Mar; 91(5A):20C-23C; discussion 23C-24C. PubMed ID: 12646340
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of low-dose rosuvastatin on plasma levels of cholesterol and oxidized low-density lipoprotein in 3 ultracentrifugally separated low-density lipoprotein subfractions.
    Homma K; Homma Y; Ozawa H; Shiina Y; Shibata T; Yoshida T; Hasegawa K; Kanda T; Tokuyama H; Wakino S; Hayashi K; Itoh H; Hori S
    J Clin Lipidol; 2015; 9(6):751-757. PubMed ID: 26687695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of carotid atherosclerosis loci on cardiovascular events.
    Hemerich D; van der Laan SW; Tragante V; den Ruijter HM; de Borst GJ; Pasterkamp G; de Bakker PI; Asselbergs FW
    Atherosclerosis; 2015 Dec; 243(2):466-8. PubMed ID: 26520901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hypolipidemic and pleiotropic effects of rosuvastatin are not enhanced by its association with zinc and selenium supplementation in coronary artery disease patients: a double blind randomized controlled study.
    Sena-Evangelista KC; Pedrosa LF; Paiva MS; Dias PC; Ferreira DQ; Cozzolino SM; Faulin TE; Abdalla DS
    PLoS One; 2015; 10(3):e0119830. PubMed ID: 25785441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of low-dose atorvastatin and rosuvastatin on plasma lipid profiles: a long-term, randomized, open-label study in patients with primary hypercholesterolemia.
    Mazza F; Stefanutti C; Di Giacomo S; Vivenzio A; Fraone N; Mazzarella B; Bucci A
    Am J Cardiovasc Drugs; 2008; 8(4):265-70. PubMed ID: 18690760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of intensive statin therapy on regression of carotid intima-media thickness in patients with subclinical carotid atherosclerosis (a prospective, randomized trial: PEACE (Pitavastatin Evaluation of Atherosclerosis Regression by Intensive Cholesterol-lowering Therapy) study).
    Ikeda K; Takahashi T; Yamada H; Matsui K; Sawada T; Nakamura T; Matsubara H;
    Eur J Prev Cardiol; 2013 Dec; 20(6):1069-79. PubMed ID: 22689416
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.